HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions. (Q34324291)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23348899%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

title

HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23348899%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23348899%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Silvano Bosari

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23348899%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Elena Guerini Rocco

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23348899%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Claudia Del Conte

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23348899%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Caterina Pellegrini

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23348899%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Gaetano Bulfamante

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23348899%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Franca Di Nuovo

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23348899%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Solange Romagnoli

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23348899%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

publication date

25 January 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23348899%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23348899%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23348899%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23348899%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

816-824

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23348899%20AND%20SRC:MED&resulttype=core&format=json

The treatment of advanced gastric cancer: current strategies and future perspectives.

22 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

HER-2 amplification is highly homogenous in gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

A study of HER2 gene amplification and protein expression in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

Overexpression of HER2/neu in solid tumours: an immunohistochemical survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

c-erb B-2 expression is associated with tumor location and venous invasion and influences survival of patients with gastric carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

Image analysis as an adjunct to manual HER-2 immunohistochemical review: a diagnostic tool to standardize interpretation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

HER-2/neu amplification is an independent prognostic factor in gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

Coamplified and overexpressed genes at ERBB2 locus in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

HER2 testing in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

Treatment of patients with advanced gastric carcinoma with a 5-fluorouracil-based or a cisplatin-based regimen: two parallel randomized phase II studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

HER-2 overexpression/amplification in Barrett's oesophagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pathologic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

Prognostic impact of body mass index stratified by smoking status in patients with esophageal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

Early HER2 dysregulation in gastric and oesophageal carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

7 January 2021

Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

7 January 2021

Close association between HER-2 amplification and overexpression in human tumors of non-breast origin

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

7 January 2021

c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

7 January 2021

HER2 testing in gastric cancer: a practical approach

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

7 January 2021

Expression of c-erbB-2 oncoprotein in gastric carcinoma: correlation with histopathologic characteristics and analysis of Ki-67

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

7 January 2021

The relationship between c-erbB-2 oncogene expression and clinicopathological factors in gastric cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

7 January 2021

Abnormal expression of E-cadherin, beta-catenin, and c-erbB-2 in advanced gastric cancer: its association with liver metastasis

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

7 January 2021

Evaluation of the epidermal growth factor receptor (EGFR) and c-erbB-2 in superspreading-type and penetrating-type gastric carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

7 January 2021

Comparative study on overexpression of HER2/neu and HER3 in gastric cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

7 January 2021

Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

7 January 2021

Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

7 January 2021

Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

7 January 2021

HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

7 January 2021

Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

7 January 2021

Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

7 January 2021

Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

7 January 2021

The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

7 January 2021

Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

7 January 2021

Clinicopathological significance of c-erbB-2 protein expression in human gastric carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

7 January 2021

The prognostic value of serum and immunohistochemical tumour markers in advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.228

7 January 2021

10.1038/MODPATHOL.2012.228

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23348899%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

22 February 2020

1009592822

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23348899%20AND%20SRC:MED&resulttype=core&format=json